FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2892779818> ?p ?o ?g. }

• W2892779818 endingPage "34078" @default.
• W2892779818 startingPage "34066" @default.
• W2892779818 abstract "// Akihito Hashizume 1 , Susumu Umemoto 1 , Tomoyuki Yokose 2 , Yoshiyasu Nakamura 3 , Mitsuyo Yoshihara 3 , Kahori Shoji 3 , Satoshi Wada 3, 4 , Yohei Miyagi 3 , Takeshi Kishida 1 and Tetsuro Sasada 3, 4 1 Department of Urology, Kanagawa Cancer Center, Yokohama, Japan 2 Department of Pathology, Kanagawa Cancer Center, Yokohama, Japan 3 Kanagawa Cancer Center Research Institute, Yokohama, Japan 4 Cancer Vaccine Center, Kanagawa Cancer Center, Yokohama, Japan Correspondence to: Tetsuro Sasada, email: tsasada@kcch.jp Takeshi Kishida, email: kishidat@kcch.jp Keywords: PD-L1; non-muscle-invasive bladder cancer; Bacillus Calmette-Guerin; CD8; immune checkpoint Received: May 01, 2018     Accepted: September 01, 2018     Published: September 25, 2018 ABSTRACT Immune checkpoint molecules, such as PD-1/PD-L1, are reported to be closely associated with suppression of antitumor immunity, and their inhibitors have been used to treat various cancers including bladder cancer. However, there have been only a few studies investigating the effects of Bacillus Calmette-Guerin (BCG) administration on expression of the immune checkpoint molecules in bladder cancer. The current study examined the expression of PD-L1 and PD-L2 before and after BCG in non-muscle-invasive bladder cancer (NMIBC) patients. Tissue microarrays of 22 BCG-resistant NMIBC patients were stained by immunohistochemistry with antibodies against PD-L1, PD-L2, and CD8, and were compared between before and after BCG. The expression levels of PD-L1, but not of PD-L2, were significantly increased after BCG treatment on tumor cells (p < 0.001) and tumor-infiltrating inflammatory cells (p = 0.030) within tumor tissues, as well as on inflammatory cells within non-tumor normal tissues (p = 0.003). Although CD8 + T cells were significantly increased within tumor tissues (p = 0.005) and non-tumor normal tissues (p = 0.007) after BCG treatment, they might be not effective for anti-tumor immunity. This study demonstrated for the first time that expression of PD-L1, which might contribute to the immune escape mechanism, was enhanced on tumor tissue after BCG treatment in BCG-resistant NMIBC patients. Our finding thus propose that immunotherapy with anti-PD-1/PD-L1 antibodies could be feasible as combination treatment with BCG or as secondary treatment at relapse after BCG in NMIBC patients." @default.
• W2892779818 created "2018-10-05" @default.
• W2892779818 creator A5000734437 @default.
• W2892779818 creator A5002389381 @default.
• W2892779818 creator A5022455287 @default.
• W2892779818 creator A5024125949 @default.
• W2892779818 creator A5028262007 @default.
• W2892779818 creator A5040876838 @default.
• W2892779818 creator A5060933834 @default.
• W2892779818 creator A5073461841 @default.
• W2892779818 creator A5076512316 @default.
• W2892779818 creator A5090248633 @default.
• W2892779818 date "2018-09-25" @default.
• W2892779818 modified "2023-10-02" @default.
• W2892779818 title "Enhanced expression of PD-L1 in non-muscle-invasive bladder cancer after treatment with Bacillus Calmette-Guerin" @default.
• W2892779818 cites W1966900148 @default.
• W2892779818 cites W1972882573 @default.
• W2892779818 cites W1983093014 @default.
• W2892779818 cites W2033577259 @default.
• W2892779818 cites W2035660473 @default.
• W2892779818 cites W2082369230 @default.
• W2892779818 cites W2084204019 @default.
• W2892779818 cites W2113964885 @default.
• W2892779818 cites W2161765043 @default.
• W2892779818 cites W2231000545 @default.
• W2892779818 cites W2340636398 @default.
• W2892779818 cites W2395763454 @default.
• W2892779818 cites W2547065851 @default.
• W2892779818 cites W2561081583 @default.
• W2892779818 cites W2582671354 @default.
• W2892779818 cites W2592065515 @default.
• W2892779818 cites W2745624257 @default.
• W2892779818 cites W2765835393 @default.
• W2892779818 cites W2771737095 @default.
• W2892779818 cites W2777192533 @default.
• W2892779818 cites W2796791442 @default.
• W2892779818 cites W2978574426 @default.
• W2892779818 cites W2988589394 @default.
• W2892779818 cites W4211115520 @default.
• W2892779818 doi "https://doi.org/10.18632/oncotarget.26122" @default.
• W2892779818 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6183350" @default.
• W2892779818 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30344922" @default.
• W2892779818 hasPublicationYear "2018" @default.
• W2892779818 type Work @default.
• W2892779818 sameAs 2892779818 @default.
• W2892779818 citedByCount "38" @default.
• W2892779818 countsByYear W28927798182019 @default.
• W2892779818 countsByYear W28927798182020 @default.
• W2892779818 countsByYear W28927798182021 @default.
• W2892779818 countsByYear W28927798182022 @default.
• W2892779818 countsByYear W28927798182023 @default.
• W2892779818 crossrefType "journal-article" @default.
• W2892779818 hasAuthorship W2892779818A5000734437 @default.
• W2892779818 hasAuthorship W2892779818A5002389381 @default.
• W2892779818 hasAuthorship W2892779818A5022455287 @default.
• W2892779818 hasAuthorship W2892779818A5024125949 @default.
• W2892779818 hasAuthorship W2892779818A5028262007 @default.
• W2892779818 hasAuthorship W2892779818A5040876838 @default.
• W2892779818 hasAuthorship W2892779818A5060933834 @default.
• W2892779818 hasAuthorship W2892779818A5073461841 @default.
• W2892779818 hasAuthorship W2892779818A5076512316 @default.
• W2892779818 hasAuthorship W2892779818A5090248633 @default.
• W2892779818 hasBestOaLocation W28927798181 @default.
• W2892779818 hasConcept C121608353 @default.
• W2892779818 hasConcept C126322002 @default.
• W2892779818 hasConcept C143998085 @default.
• W2892779818 hasConcept C193270364 @default.
• W2892779818 hasConcept C203014093 @default.
• W2892779818 hasConcept C204232928 @default.
• W2892779818 hasConcept C2777701055 @default.
• W2892779818 hasConcept C2780352672 @default.
• W2892779818 hasConcept C2780674031 @default.
• W2892779818 hasConcept C2780851360 @default.
• W2892779818 hasConcept C2781053074 @default.
• W2892779818 hasConcept C502942594 @default.
• W2892779818 hasConcept C71924100 @default.
• W2892779818 hasConcept C8891405 @default.
• W2892779818 hasConceptScore W2892779818C121608353 @default.
• W2892779818 hasConceptScore W2892779818C126322002 @default.
• W2892779818 hasConceptScore W2892779818C143998085 @default.
• W2892779818 hasConceptScore W2892779818C193270364 @default.
• W2892779818 hasConceptScore W2892779818C203014093 @default.
• W2892779818 hasConceptScore W2892779818C204232928 @default.
• W2892779818 hasConceptScore W2892779818C2777701055 @default.
• W2892779818 hasConceptScore W2892779818C2780352672 @default.
• W2892779818 hasConceptScore W2892779818C2780674031 @default.
• W2892779818 hasConceptScore W2892779818C2780851360 @default.
• W2892779818 hasConceptScore W2892779818C2781053074 @default.
• W2892779818 hasConceptScore W2892779818C502942594 @default.
• W2892779818 hasConceptScore W2892779818C71924100 @default.
• W2892779818 hasConceptScore W2892779818C8891405 @default.
• W2892779818 hasIssue "75" @default.
• W2892779818 hasLocation W28927798181 @default.
• W2892779818 hasLocation W28927798182 @default.
• W2892779818 hasLocation W28927798183 @default.
• W2892779818 hasLocation W28927798184 @default.
• W2892779818 hasOpenAccess W2892779818 @default.
• W2892779818 hasPrimaryLocation W28927798181 @default.

• next